Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SpongillaTech is an innovative biotechnology company focused on the development of advanced biomaterials derived from freshwater sponges. The company leverages a proprietary extraction process to produce high-purity collagen and other bioactive compounds that serve as scaffolds for tissue engineering and regenerative medicine. Their primary technology involves the creation of biocompatible hydrogels and membranes designed to accelerate wound healing and support skin repair. SpongillaTech's products are positioned for use in both clinical dermatology and aesthetic medicine, offering a sustainable alternative to bovine or porcine-derived collagen. By utilizing unique aquatic biological sources, the company aims to provide superior structural integrity and bio-absorption profiles for complex medical applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SpongillaTech.